SubHero Banner

Trisenox® (arsenic trioxide) – New indication

January 15, 2018 - Teva announced the FDA approval of Trisenox (arsenic trioxide) in combination with tretinoin for the treatment of adults with newly diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

Download PDF